Compare YOUL & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YOUL | LITS |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 36.3M |
| IPO Year | 2024 | 2003 |
| Metric | YOUL | LITS |
|---|---|---|
| Price | $0.14 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 408.3K | 257.2K |
| Earning Date | 10-15-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.81 |
| EPS | N/A | ★ 0.48 |
| Revenue | N/A | N/A |
| Revenue This Year | $12.28 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | ★ N/A | $1.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.09 | $0.69 |
| 52 Week High | $2.13 | $1.99 |
| Indicator | YOUL | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 36.17 |
| Support Level | N/A | $0.69 |
| Resistance Level | $0.36 | $1.24 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 15.98 | 22.59 |
Youlife Group Inc is a blue-collar lifetime service platform in China, dedicated to serving the needs throughout the entire life cycle of the blue-collar talent. It provides blue-collar lifetime services to students, blue-collar talent, and corporate customers. Its segments are the vocational education segment, which engages in the provision of vocational education entrusted management services, self-operated vocational school services, and Others; the HR recruitment segment engages in the provision of HR recruitment services regarding blue-collar talent to customers; the employee management segment engages in the provision of labor outsourcing services, labor dispatch services and others; and the market service segment engages in the provision of value-added services.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.